The only thing I'd mention here is that if you look over time at the number of negative recommendations that have been made by CDR that resulted in positive recommendations by other provinces or drug plans, you actually see some variation. You see some 14 drugs listed in Quebec, even though they are not a participating plan, that received a negative recommendation from CDR. You see the NIHB with one or so. B.C., I believe, has listed a few that have received negative recommendations, and Ontario has listed 4 drugs that have received negative recommendations.
It just goes to the point that Mr. Williams raised earlier, and it really goes to the heart of the question of catastrophic drugs. Provinces are best placed to make decisions with regard to health care, and they do that across all other medically necessary services, so the question has to be who is best placed to make these decisions. It's our position that it certainly isn't a macro group, even if they are providing recommendations, as you'll certainly hear next week.
The fact is that those end up being de facto decisions in terms of what it means from the individual patient's point of view: do I have a choice of getting this or not? When you see those negative recommendations resulting in waits for a decision that may or may not come from a province, or a negative so we're not listing it, that really ends up being a de facto decision that harms patients.